Molecular Signaling Mediated by Angiotensin II Type 1A Receptor Blockade Leading to Attenuation of Renal Dysfunction-Associated Heart Failure

Journal of Cardiac Failure

Volumn 13, Issue 2, 2007, Pages 155-162

  Li, Yiwen ^a,b   Takemura, Genzou ^a   Okada, Hideshi ^a   Miyata, Shusaku ^a   Maruyama, Rumi ^a   Esaki, Masayasu ^a   Kanamori, Hiromitsu ^a   Li, Longhu ^a   Ogino, Atsushi ^a   Ohno, Takamasa ^a   Kondo, Takehito ^a   Nakagawa, Munehiro ^a   Minatoguchi, Shinya ^a   Fujiwara, Takako ^c   Fujiwara, Hisayoshi ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c KYOTO WOMEN'S UNIVERSITY   (Japan)

Author keywords

Angiotensin receptors; Experimental models; Heart failure; Renal failure

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 1A RECEPTOR; GELATINASE A; GELATINASE B; HYDRALAZINE; PHOSPHOPROTEIN; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENE EXPRESSION; HEART DILATATION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KNOCKOUT MOUSE; MALE; MOUSE; NEPHRECTOMY; NONHUMAN; OSMOTIC MINIPUMP; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STRAIN DIFFERENCE; UPREGULATION; WILD TYPE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD UREA NITROGEN; BLOTTING, WESTERN; CREATININE; DISEASE MODELS, ANIMAL; DNA; HEART FAILURE, CONGESTIVE; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIUM; NEPHRECTOMY; OXIDATIVE STRESS; RECEPTOR, ANGIOTENSIN, TYPE 1; SIGNAL TRANSDUCTION; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; UP-REGULATION; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 33947492150     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2006.11.005     Document Type: Article

References (37)

1. Foley R.N., Parfrey P.S., and Sarnak M. Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 (1998) s112-s119
2. Silberberg J., Barre P.E., Prichard S.S., and Sniderman A.D. Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36 (1989) 286-290
3. Grossman W. Cardiac hypertrophy: useful adaptation or pathologic process?. Am J Med 69 (1980) 576-584
4. Tyralla K., and Amann K. Cardiovascular changes in renal failure. Blood Purif 20 (2002) 462-465
5. London G.M. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant 17 (2002) 29-36
6. Brunner H.R. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 87 (2001) 3C-9C
7. Shibasaki Y., Nishiue T., Masaki H., Matsubara H., and Iwasaka T. Angiotensin II type 1 antagonist suppress left ventricular hypertrophy and myocardial fibrosis in patient with end stage renal disease (ESRD). [in Japanese]. Nippon Rinsho 60 (2002) 1992-1998
8. Li Y., Takemura G., Okada H., Miyata S., Esaki M., Maruyama R., et al. Treatment with granulocyte colony-stimulating factor ameliorates chronic heart failure. Lab Invest 86 (2006) 32-44
9. Sugaya T., Nishimatsu S., Tanimoto K., Takimoto E., Yamagishi T., Imamura K., et al. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270 (1995) 18719-18722
10. Uegaito T., Fujiwara H., Ishida M., Kawamura A., Takemura G., Kida M., et al. Hypertrophy of surviving myocytes overlying the infarct in human old myocardial infarctions with abnormal Q waves. Int J Cardiol 32 (1991) 93-101
11. Toyokuni S., Tanaka T., Hattori Y., Nishiyama Y., Yoshida A., Uchida K., et al. Quantitative immunohistochemical determination of 8-hydroxy-2′-deoxyguanosine by a monoclonal antibody N45.1: its application to ferric nitrilotriacetate-induced renal carcinogenesis model. Lab Invest 76 (1997) 365-374
12. Toyokuni S., Uchida K., Okamoto K., Hattori-Nakakuki Y., Hiai H., and Stadtman E.R. Formation of 4-hydroxy-2-nonenal-modified proteins in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci U S A 91 (1994) 2616-2620
13. Rosenkranz S., Flesch M., Amann K., Haeuseler C., Kilter H., Seeland U., et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 283 (2002) H1253-H1262
14. Jiang B.H., Zheng J.Z., Aoki M., and Vogt P.K. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A 97 (2000) 1749-1753
15. Nakamura T., Kanno Y., Takenaka T., and Suzuki H. An angiotensin receptor blocker reduces the risk of congestive heart failure in elderly hypertensive patients with renal insufficiency. Hypertens Res 28 (2005) 415-423
16. Shibasaki Y., Masaki H., Nishiue T., Nishikawa M., Matsubara H., and Iwasaka T. Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90 (2002) 256-261
17. Kawano H., Do Y.S., Kawano Y., Starnes V., Barr M., Law R.E., et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 101 (2000) 1130-1137
18. Varagic J., and Frohlich E.D. Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 34 (2002) 1435-1442
19. Varo N., Etayo J., Zalba G., Monreal I., and Diez J. Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17 (1999) 107-114
20. Schultz J.J., Witt S.A., Glascock B.J., Nieman M.L., Reiser P.J., Nix S.L., et al. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest 109 (2002) 787-796
21. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
22. Ali S.M., Laping N.J., Fredrickson T.A., Contino L.C., Olson B., Anderson K., et al. Angiotensin-converting enzyme inhibition attenuates proteinuria and renal TGF-β1 mRNA expression in rats with chronic renal disease. Pharmacology 57 (1998) 20-27
23. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90 (2002) 520-530
24. Heymans S., Schroen B., Vermeersch P., Milting H., Gao F., Kassner A., et al. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 112 (2005) 1136-1144
25. Panek A.N., and Bader M. Matrix reloaded: the matrix metalloproteinase paradox. Hypertension 47 (2006) 640-641
26. Chen X., Wang J., Zhou F., Wang X., and Feng Z. STAT proteins mediate angiotensin II-induced production of TIMP-1 in human proximal tubular epithelial cells. Kidney Int 64 (2003) 459-467
27. Gomez D.E., Alonso D.F., Yoshiji H., and Thorgeirsson U.P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74 (1997) 111-122
28. Chirco R., Liu X.W., Jung K.K., and Kim H.R. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25 (2006) 99-113
29. Nickenig G., and Harrison D.G. The AT (1)-type angiotensin receptor in oxidative stress and atherogenesis: part I: oxidative stress and atherogenesis. Circulation 105 (2002) 393-396
30. Beckman J.S., and Koppenol W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 271 (1996) C1424-C1437
31. Laursen J.B., Somers M., Kurz S., McCann L., Warnholtz A., Freeman B.A., et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 103 (2001) 1282-1288
32. Goligorsky M.S., Li H., Brodsky S., and Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 283 (2002) F1-F10
33. Dimmeler S., Fleming I., Fisslthaler B., Hermann C., Busse R., and Zeiher A.M. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
34. Friebe A., and Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93 (2003) 96-105
35. Sindhu R.K., Ehdaie A., Vaziri N.D., and Robert C.K. Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochim Biophys Acta 1690 (2004) 231-237
36. Ma F.X., and Han Z.C. Akt signaling and its role in postnatal neovascularization. Histol Histopathol 20 (2005) 275-281
37. Silvestre J.S., Mallat Z., Tamarat R., Dariez M., Tedgui A., and Levy B.I. Regulation of matrix metalloproteinase activity in ischemic tissue by interleukin-10: role in ischemia-induced angiogenesis. Circ Res 89 (2001) 259-264